MYC重排及易位伙伴基因在弥漫大B细胞淋巴瘤中的预后意义:Lunenburg淋巴瘤生物标志物联盟研究
该研究基于Lunenburg联盟多中心队列,纳入5117例经组织学确诊的DLBCL患者,其中2383例有活检组织可评估MYC重排。264例(11%)存在MYC重排,与无进展生存和总生存显著缩短相关,且不良预后仅见于同时伴BCL2和/或BCL6重排且MYC与免疫球蛋白(IG)伙伴基因易位的患者(HR=2.4,95%CI 1.6-3.6,P<.001),该效应局限于诊断后前24个月。
要点
- MYC重排见于11%的DLBCL患者,与不良生存相关。
- 不良预后仅见于MYC伴IG伙伴基因且合并BCL2/BCL6重排者。
- MYC重排的不良效应局限于诊断后前24个月。
核心结论
- MYC重排的不良预后主要见于MYC双打击/三打击且MYC易位至IG伙伴基因的DLBCL患者,且效应局限于诊断后前2年。
研究设计与样本
- 研究队列来自欧洲和北美大型前瞻性试验及患者登记,纳入组织学确诊的DLBCL患者,均接受利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)或类似方案治疗。
- 采用荧光原位杂交检测MYC、BCL2、BCL6及IG重链和轻链基因座,并将结果与临床结局关联。
- 共识别5117例患者,其中2383例(47%)有活检材料可评估MYC重排。
主要发现
- 2383例可评估患者中264例(11%)存在MYC重排。
- MYC重排与无进展生存和总生存显著缩短相关,且在诊断后前24个月内呈强时间依赖性效应。
- MYC重排的不良预后影响仅见于同时伴BCL2和/或BCL6重排且MYC与IG伙伴基因易位的患者(风险比2.4,95%CI 1.6-3.6,P<.001)。
关键数值与推荐
- MYC重排定义为荧光原位杂交检测MYC基因座重排。
- 双打击/三打击状态定义为MYC重排同时伴BCL2和/或BCL6重排。
- 高危亚组定义为MYC重排伴IG伙伴基因且合并BCL2和/或BCL6重排,风险比2.4(95%CI 1.6-3.6,P<.001)。
临床怎么用
- 诊断时应采用荧光原位杂交检测MYC、BCL2和BCL6重排,以识别高危MYC双打击/三打击且IG伙伴基因的DLBCL患者。
- 对识别出的高危患者,可考虑进一步优化风险调整治疗策略。
局限性
- 仅47%的患者有活检材料可评估MYC重排,可能存在选择偏倚。
- 研究为回顾性分析活检材料与临床结局的相关性,非前瞻性干预研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic significance of MYC-R (single-, double-, and triple-hit status) in DLBCL within the context of the MYC partner gene. METHODS: The study cohort included patients with histologically confirmed DLBCL morphology derived from large prospective trials and patient registries in Europe and North America who were uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy or the like. Fluorescence in situ hybridization for the MYC, BCL2, BCL6, and IG heavy and light chain loci was used, and results were correlated with clinical outcomes. RESULTS: A total of 5,117 patients were identified of whom 2,383 (47%) had biopsy material available to assess for MYC-R. MYC-R was present in 264 (11%) of 2,383 patients and was associated with a significantly shorter progression-free and overall survival, with a strong time-dependent effect within the first 24 months after diagnosis. The adverse prognostic impact of MYC-R was only evident in patients with a concurrent rearrangement of BCL2 and/or BCL6 and an IG partner (hazard ratio, 2.4; 95% CI, 1.6 to 3.6; P < .001). CONCLUSION: The negative prognostic impact of MYC-R in DLBCL is largely observed in patients with MYC double hit/triple-hit disease in which MYC is translocated to an IG partner, and this effect is restricted to the first 2 years after diagnosis. Our results suggest that diagnostic strategies should be adopted to identify this high-risk cohort, and risk-adjusted therapeutic approaches should be refined further.
引用
- Rosenwald A, Bens S, Advani R, et al. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019. PMID: 31498031. doi:10.1200/JCO.19.00743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。